Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Cystadenocarcinoma, Serous"" wg kryterium: Temat


Tytuł:
Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer-Genetic Instability and Clinical Implications.
Autorzy:
Murawski M; 1st Clinical Department of Gynecology and Obstetrics, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Jagodziński A; 1st Clinical Department of Gynecology and Obstetrics, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Bielawska-Pohl A; Laboratory of Biology of Stem and Neoplastic Cells, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Klimczak A; Laboratory of Biology of Stem and Neoplastic Cells, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Pokaż więcej
Źródło:
Cells [Cells] 2024 Feb 15; Vol. 13 (4). Date of Electronic Publication: 2024 Feb 15.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
Cystadenocarcinoma, Serous*/genetics
Female ; Humans ; BRCA1 Protein/genetics ; Tumor Suppressor Protein p53/genetics ; Proto-Oncogene Proteins B-raf/genetics ; Phosphatidylinositol 3-Kinases/genetics ; Proto-Oncogene Proteins p21(ras)/genetics ; BRCA2 Protein/genetics ; Carcinogenesis ; Cell Transformation, Neoplastic ; Class I Phosphatidylinositol 3-Kinases/genetics ; Genetic Background
Czasopismo naukowe
Tytuł:
[Antitumor effects of redox-responsive nanoparticles containing platinum(Ⅳ)in ovarian cancer].
Autorzy:
Hou HY; Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
Tang DS; Beijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
Zhang YN; Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Wang KY; Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Ao M; Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Luo HX; Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Li B; Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2024 Jan 23; Vol. 46 (1), pp. 76-85.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Ovarian Neoplasms*/drug therapy
Cystadenocarcinoma, Serous*
Humans ; Female ; Animals ; Mice ; Platinum ; Cisplatin/pharmacology ; Cell Line, Tumor ; Ki-67 Antigen ; Carcinoma, Ovarian Epithelial ; Disease Models, Animal ; Eosine Yellowish-(YS) ; Necrosis ; Polymers ; Body Weight
Czasopismo naukowe
Tytuł:
The comparison of pure uterine serous carcinoma and mixed tumor with serous component: a single-institution review of 91 cases.
Autorzy:
You X; Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, P. R. China.
Dong Y; Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, P. R. China.
Wang J; Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, P. R. China.
Cheng Y; Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, P. R. China.
Jia Y; Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, P. R. China.
Zhang X; Department of Pathology, Peking University People's Hospital, Beijing, 100044, P. R. China.
Wang J; Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, P. R. China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Jan 17; Vol. 24 (1), pp. 99. Date of Electronic Publication: 2024 Jan 17.
Typ publikacji:
Journal Article
MeSH Terms:
Uterine Neoplasms*/pathology
Cystadenocarcinoma, Serous*/pathology
Female ; Humans ; Retrospective Studies ; Neoplasm Recurrence, Local/pathology ; Recurrence ; Neoplasm Staging
Czasopismo naukowe
Tytuł:
ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1.
Autorzy:
Li YK; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Gao AB; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.; Clinical Research Institute, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Zeng T; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Liu D; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.
Zhang QF; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Ran XM; Department of Gynecologic Oncology, School of Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya, Central South University, Changsha, Hunan, China.
Tang ZZ; Department of Gynecologic Oncology, School of Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya, Central South University, Changsha, Hunan, China.
Li Y; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.
Liu J; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Zhang T; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Shi GQ; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Zhou WC; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Zou WD; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.
Peng J; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China.
Zhang J; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China. .
Li H; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China. lihui_.
Zou J; Department of Assisted Reproductive Centre, Zhuzhou Central Hospital, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, Hunan, China. .; The Second Affiliated Hospital, Department of Gynecology, Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Jan 11; Vol. 22 (1), pp. 46. Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:
Journal Article
MeSH Terms:
Cystadenocarcinoma, Serous*
Ovarian Neoplasms*/genetics
STAT3 Transcription Factor*
Janus Kinase 2*
Animals ; Female ; Humans ; Tumor Microenvironment ; Molecular Docking Simulation ; Angiogenesis ; Zebrafish/metabolism ; Carcinogenesis ; Cell Proliferation ; Carcinoma, Ovarian Epithelial ; Cell Line, Tumor ; Angiopoietin-Like Protein 4/genetics ; Neoplasm Proteins ; Proteoglycans
Czasopismo naukowe
Tytuł:
Human Fallopian Tube-Derived Organoids with TP53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous Ovarian Cancer Phenotype In Vitro.
Autorzy:
Dai Y; Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China.
Xu J; Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China.
Gong X; State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai 200438, China.
Wei J; State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai 200438, China.
Gao Y; Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China.
Chai R; Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China.
Lu C; Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China.
Zhao B; State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai 200438, China.
Kang Y; Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 10; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 10.
Typ publikacji:
Journal Article
MeSH Terms:
Cystadenocarcinoma, Serous*/genetics
Ovarian Neoplasms*/genetics
Humans ; Female ; Fallopian Tubes ; Carcinoma, Ovarian Epithelial ; Mutation ; Tumor Suppressor Protein p53/genetics ; DNA-Binding Proteins
Czasopismo naukowe
Tytuł:
Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation.
Autorzy:
Karakas C; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Giampoli EJ; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Love T; Department of Biostatistics and Computation Biology, University of Rochester, Rochester, NY, USA.
Hicks DG; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Velez MJ; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. Moises_.
Pokaż więcej
Źródło:
Diagnostic pathology [Diagn Pathol] 2024 Jan 10; Vol. 19 (1), pp. 10. Date of Electronic Publication: 2024 Jan 10.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma*
Cystadenocarcinoma, Serous*
Humans ; Cytoplasm ; Immunohistochemistry ; Introns ; Receptor Protein-Tyrosine Kinases
Czasopismo naukowe
Tytuł:
Identification of serum miR-1246 and miR-150-5p as novel diagnostic biomarkers for high-grade serous ovarian cancer.
Autorzy:
Niemira M; Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland. .
Erol A; Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
Bielska A; Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
Zeller A; Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
Skwarska A; Cancer Center, Department of Oncology, Albert Einstein College of Medicine, Bronx, NY, USA.
Chwialkowska K; Centre for Bioinformatics and Data Analysis, Medical University of Bialystok, Bialystok, Poland.
Kuzmicki M; Department of Gynecology and Gynecological Oncology, Medical University of Bialystok, Bialystok, Poland.
Szamatowicz J; Department of Gynecology and Gynecological Oncology, Medical University of Bialystok, Bialystok, Poland.
Reszec J; Department of Medical Pathomorphology, Medical University of Bialystok, Bialystok, Poland.
Knapp P; University Oncology Centre, University Clinical Hospital in Bialystok, Bialystok, Poland.
Moniuszko M; Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.
Kretowski A; Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Nov 07; Vol. 13 (1), pp. 19287. Date of Electronic Publication: 2023 Nov 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
MicroRNAs*
Ovarian Neoplasms*/diagnosis
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/metabolism
Cystadenocarcinoma, Serous*/diagnosis
Cystadenocarcinoma, Serous*/genetics
Cystadenocarcinoma, Serous*/pathology
Humans ; Female ; Carcinoma, Ovarian Epithelial/diagnosis ; Carcinoma, Ovarian Epithelial/genetics ; Biomarkers, Tumor
Czasopismo naukowe
Tytuł:
PTPN13 Participates in the Regulation of Epithelial-Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells.
Autorzy:
Aptecar L; IRCM (Institut de Recherche en Cancérologie de Montpellier), University of Montpellier, Inserm, ICM (Institut du Cancer de Montpellier), F-34000 Montpellier, France.
Puech C; IRCM (Institut de Recherche en Cancérologie de Montpellier), University of Montpellier, Inserm, ICM (Institut du Cancer de Montpellier), F-34000 Montpellier, France.
Lopez-Crapez E; IRCM (Institut de Recherche en Cancérologie de Montpellier), University of Montpellier, Inserm, ICM (Institut du Cancer de Montpellier), F-34000 Montpellier, France.
Peter M; IRCM (Institut de Recherche en Cancérologie de Montpellier), University of Montpellier, Inserm, ICM (Institut du Cancer de Montpellier), F-34000 Montpellier, France.; CNRS-Centre National de la Recherche Scientifique, 1919 Route de Mende, F-34293 Montpellier, France.
Coopman P; IRCM (Institut de Recherche en Cancérologie de Montpellier), University of Montpellier, Inserm, ICM (Institut du Cancer de Montpellier), F-34000 Montpellier, France.; CNRS-Centre National de la Recherche Scientifique, 1919 Route de Mende, F-34293 Montpellier, France.
D'Hondt V; IRCM (Institut de Recherche en Cancérologie de Montpellier), University of Montpellier, Inserm, ICM (Institut du Cancer de Montpellier), F-34000 Montpellier, France.
Freiss G; IRCM (Institut de Recherche en Cancérologie de Montpellier), University of Montpellier, Inserm, ICM (Institut du Cancer de Montpellier), F-34000 Montpellier, France.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Oct 21; Vol. 24 (20). Date of Electronic Publication: 2023 Oct 21.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
Cystadenocarcinoma, Serous*/drug therapy
Cystadenocarcinoma, Serous*/genetics
Cystadenocarcinoma, Serous*/metabolism
Female ; Humans ; Epithelial-Mesenchymal Transition/genetics ; Carcinoma, Ovarian Epithelial/genetics ; Phenotype ; Cell Line, Tumor ; Protein Tyrosine Phosphatase, Non-Receptor Type 13/genetics
Czasopismo naukowe
Tytuł:
Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomes.
Autorzy:
Robertson SE; Department of Gynecology Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America.
Yasukawa M; Department of Gynecology Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America.
Marchion DC; Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America.
Xiong Y; Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America.
Naqvi SMH; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America.
Gheit T; International Agency for Research on Cancer, World Health Organization, Lyon, France.
Tommasino M; International Agency for Research on Cancer, World Health Organization, Lyon, France.
Wenham RM; Department of Gynecology Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America.; Department of Oncologic Sciences, University of South Florida, Tampa, Florida, United States of America.
Giuliano AR; Risk Assessment, Detection and Intervention Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America.
Lancaster JM; Department of Gynecology Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America.; Department of Oncologic Sciences, University of South Florida, Tampa, Florida, United States of America.
Shahzad MMK; Department of Gynecology Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America.; Department of Oncologic Sciences, University of South Florida, Tampa, Florida, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Dec 01; Vol. 18 (12), pp. e0294448. Date of Electronic Publication: 2023 Dec 01 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Epstein-Barr Virus Infections*
Ovarian Neoplasms*/epidemiology
Ovarian Neoplasms*/genetics
Cystadenocarcinoma, Serous*/pathology
Humans ; Female ; Infant ; Aged ; Carcinoma, Ovarian Epithelial/epidemiology ; Carcinoma, Ovarian Epithelial/genetics ; DNA, Viral/genetics ; Prevalence ; Herpesvirus 4, Human/genetics
Czasopismo naukowe
Tytuł:
Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response.
Autorzy:
Yang H; Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, National Clinical Research Center for Obstetric & Gynecologic Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuai Fu Yuan, Wang Fu Jing Street, Beijing, China.
Gu X; Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, National Clinical Research Center for Obstetric & Gynecologic Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuai Fu Yuan, Wang Fu Jing Street, Beijing, China.; 4+4 Medical Doctor Program, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Fan R; Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, National Clinical Research Center for Obstetric & Gynecologic Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuai Fu Yuan, Wang Fu Jing Street, Beijing, China.
Zhu Q; Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, National Clinical Research Center for Obstetric & Gynecologic Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuai Fu Yuan, Wang Fu Jing Street, Beijing, China.; Department of Obstetrics and Gynecology, Beijing Puren Hospital, Beijing, China.
Zhong S; Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, National Clinical Research Center for Obstetric & Gynecologic Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuai Fu Yuan, Wang Fu Jing Street, Beijing, China.
Wan X; Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, National Clinical Research Center for Obstetric & Gynecologic Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuai Fu Yuan, Wang Fu Jing Street, Beijing, China.
Chen Q; Thorgene Co., Ltd, Beijing, China.
Zhu L; Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, National Clinical Research Center for Obstetric & Gynecologic Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuai Fu Yuan, Wang Fu Jing Street, Beijing, China. zhu_.
Feng F; Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, National Clinical Research Center for Obstetric & Gynecologic Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuai Fu Yuan, Wang Fu Jing Street, Beijing, China. .
Pokaż więcej
Źródło:
Journal of ovarian research [J Ovarian Res] 2023 Nov 22; Vol. 16 (1), pp. 223. Date of Electronic Publication: 2023 Nov 22.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/genetics
Carcinoma, Endometrioid*/therapy
Cystadenocarcinoma, Serous*/pathology
Humans ; Female ; Carcinoma, Ovarian Epithelial/pathology ; Tumor Microenvironment ; Immunotherapy
Czasopismo naukowe
Tytuł:
Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers.
Autorzy:
Azzalini E; Department of Medical Sciences (DSM), University of Trieste, 34149 Trieste, Italy.
Stanta G; Department of Medical Sciences (DSM), University of Trieste, 34149 Trieste, Italy.
Canzonieri V; Department of Medical Sciences (DSM), University of Trieste, 34149 Trieste, Italy.; Pathology Unit, Centro di Riferimento Oncologico (CRO) IRCCS, Aviano-National Cancer Institute, 33081 Pordenone, Italy.
Bonin S; Department of Medical Sciences (DSM), University of Trieste, 34149 Trieste, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Oct 11; Vol. 24 (20). Date of Electronic Publication: 2023 Oct 11.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Ovarian Neoplasms*/pathology
Cystadenocarcinoma, Serous*/pathology
Humans ; Female ; Carcinoma, Ovarian Epithelial/genetics ; Carcinoma, Ovarian Epithelial/pathology ; Mutation ; Tumor Microenvironment/genetics
Czasopismo naukowe
Tytuł:
Current Laboratory Testing Practices for Assessment of ERBB2/HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma.
Autorzy:
Hagemann IS; From the Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri (Hagemann).
Bridge JA; ProPath, Dallas, Texas (Bridge).; The Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Bridge).
Tafe LJ; The Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire (Tafe).
Hameed MR; The Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Hameed).
Moncur JT; The Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Moncur).
Bellizzi AM; The Department of Pathology, University of Iowa, Iowa City (Bellizzi).
Dolan M; The Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis (Dolan).
Vasalos P; The Proficiency Testing Department (Vasalos, Kane), College of American Pathologists, Northfield, Illinois.
Kane ME; The Proficiency Testing Department (Vasalos, Kane), College of American Pathologists, Northfield, Illinois.
Souers RJ; The Biostatistics Department (Souers), College of American Pathologists, Northfield, Illinois.
Yemelyanova A; The Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York (Yemelyanova).
Pokaż więcej
Źródło:
Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2023 Oct 01; Vol. 147 (10), pp. 1148-1157.
Typ publikacji:
Journal Article
MeSH Terms:
Endometrial Neoplasms*/diagnosis
Cystadenocarcinoma, Serous*
Breast Neoplasms*/diagnosis
Breast Neoplasms*/metabolism
Stomach Neoplasms*/pathology
Esophageal Neoplasms*/pathology
Colorectal Neoplasms*/diagnosis
Female ; Humans ; United States ; In Situ Hybridization, Fluorescence ; Receptor, ErbB-2/genetics ; Biomarkers, Tumor/metabolism
Czasopismo naukowe
Tytuł:
Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review.
Autorzy:
Lazurko C; Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
Linder R; Department of Obstetrics and Gynecology, Rambam Health Care Campus, Haifa 3109601, Israel.
Pulman K; Division of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON L5M 2N1, Canada.
Lennox G; Division of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON L5M 2N1, Canada.
Feigenberg T; Division of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON L5M 2N1, Canada.
Fazelzad R; Department of Library and Information Services, University Health Network Library and Information Services, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada.
May T; Division of Gynecologic Oncology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G 2M9, Canada.
Zigras T; Division of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON L5M 2N1, Canada.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Sep 03; Vol. 30 (9), pp. 8159-8171. Date of Electronic Publication: 2023 Sep 03.
Typ publikacji:
Systematic Review; Journal Article; Review
MeSH Terms:
Cystadenocarcinoma, Serous*/diagnosis
Cystadenocarcinoma, Serous*/drug therapy
Cystadenocarcinoma, Serous*/pathology
Peritoneal Neoplasms*/drug therapy
Ovarian Neoplasms*/diagnosis
Humans ; Female ; Bevacizumab/pharmacology ; Bevacizumab/therapeutic use ; Prospective Studies ; Carcinoma, Ovarian Epithelial/drug therapy
Czasopismo naukowe
Tytuł:
Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas.
Autorzy:
Arias-Diaz AE; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain.; Department of Medicine, Universidade de Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain.
Ferreiro-Pantin M; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain.
Barbazan J; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain.; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain.
Perez-Beliz E; Department of Pathology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain.
Ruiz-Bañobre J; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain.; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain.
Casas-Arozamena C; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain.; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain.
Muinelo-Romay L; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain.; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain.
Lopez-Lopez R; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain.; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain.
Vilar A; Department of Gynecology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain.
Curiel T; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain.; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain.
Abal M; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain.; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Aug 25; Vol. 24 (17). Date of Electronic Publication: 2023 Aug 25.
Typ publikacji:
Journal Article
MeSH Terms:
Ascites*
Cystadenocarcinoma, Serous*/drug therapy
Cystadenocarcinoma, Serous*/genetics
Humans ; Female ; Organoids ; Peritoneum ; Ascitic Fluid
Czasopismo naukowe
Tytuł:
AhRR and PPP1R3C: Potential Prognostic Biomarkers for Serous Ovarian Cancer.
Autorzy:
Ardizzoia A; School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
Jemma A; School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
Redaelli S; School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
Silva M; School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
Bentivegna A; School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
Lavitrano M; School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
Conconi D; School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Jul 14; Vol. 24 (14). Date of Electronic Publication: 2023 Jul 14.
Typ publikacji:
Journal Article
MeSH Terms:
Cystadenocarcinoma, Serous*/diagnosis
Cystadenocarcinoma, Serous*/genetics
Cystadenocarcinoma, Serous*/metabolism
Ovarian Neoplasms*/diagnosis
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/metabolism
Female ; Humans ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Carcinoma, Ovarian Epithelial/pathology ; DNA Copy Number Variations/genetics ; Intracellular Signaling Peptides and Proteins/metabolism ; Neoplastic Stem Cells/metabolism ; Prognosis
Czasopismo naukowe
Tytuł:
Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging.
Autorzy:
Miyagawa C; Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Nakai H; Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. .
Otani T; Department of Pathology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Murakami R; Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takamura S; Department of Immunology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Takaya H; Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Murakami K; Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Mandai M; Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Matsumura N; Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Pokaż więcej
Źródło:
Journal of gynecologic oncology [J Gynecol Oncol] 2023 Jul; Vol. 34 (4), pp. e47. Date of Electronic Publication: 2023 Feb 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Ovarian Neoplasms*/diagnostic imaging
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
Cystadenocarcinoma, Serous*/diagnostic imaging
Cystadenocarcinoma, Serous*/genetics
Cystadenocarcinoma, Serous*/pathology
Humans ; Female ; Prognosis ; Gene Expression Profiling/methods
Czasopismo naukowe
Tytuł:
Morphological and Immunocytochemical Characterization of Tumor Spheroids in Ascites from High-Grade Serous Carcinoma.
Autorzy:
Miceska S; Department of Cytopathology, Institute of Oncology Ljubljana, Zaloška Cesta 2, 1000 Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Korytkova Ulica 2, 1000 Ljubljana, Slovenia.
Škof E; Faculty of Medicine, University of Ljubljana, Korytkova Ulica 2, 1000 Ljubljana, Slovenia.; Department of Medical Oncology, Institute of Oncology Ljubljana, Zaloška Cesta 2, 1000 Ljubljana, Slovenia.
Gašljević G; Department of Pathology, Institute of Oncology Ljubljana, Zaloška Cesta 2, 1000 Ljubljana, Slovenia.; Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia.
Kloboves-Prevodnik V; Department of Cytopathology, Institute of Oncology Ljubljana, Zaloška Cesta 2, 1000 Ljubljana, Slovenia.; Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Sep 30; Vol. 12 (19). Date of Electronic Publication: 2023 Sep 30.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Ovarian Neoplasms*/pathology
Cystadenocarcinoma, Serous*/pathology
Humans ; Female ; B7-H1 Antigen/metabolism ; Ascites/pathology ; Programmed Cell Death 1 Receptor ; Lymphocytes, Tumor-Infiltrating
Czasopismo naukowe
Tytuł:
Evaluating the Utility of ctDNA in Detecting Residual Cancer and Predicting Recurrence in Patients with Serous Ovarian Cancer.
Autorzy:
Zhu JW; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5S 1B2, Canada.; Department of Medicine, McMaster University, Hamilton, ON L8P 1H6, Canada.
Wong F; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5S 1B2, Canada.; Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
Szymiczek A; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5S 1B2, Canada.
Ene GEV; Division of Gynecologic Oncology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G 2M9, Canada.
Zhang S; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5S 1B2, Canada.
May T; Division of Gynecologic Oncology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G 2M9, Canada.; Division of Gynecologic Oncology, Department of Obstetric and Gynecology, University of Toronto, Toronto, ON M5G 2C4, Canada.
Narod SA; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5S 1B2, Canada.; Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.; Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada.
Kotsopoulos J; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5S 1B2, Canada.; Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada.
Akbari MR; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5S 1B2, Canada.; Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.; Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Sep 21; Vol. 24 (18). Date of Electronic Publication: 2023 Sep 21.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/diagnosis
Ovarian Neoplasms*/genetics
Cystadenocarcinoma, Serous*
Cell-Free Nucleic Acids*
Humans ; Female ; Neoplasm, Residual/genetics ; Neoplasm Recurrence, Local/genetics ; Carcinoma, Ovarian Epithelial ; Oncogenes
Czasopismo naukowe
Tytuł:
Gain-of-function p53 blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma.
Autorzy:
Haagsma J; The Mary and John Knight Translational Ovarian Cancer Research Unit, London Regional Cancer Program, London, ON, Canada.; Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Kolendowski B; The Mary and John Knight Translational Ovarian Cancer Research Unit, London Regional Cancer Program, London, ON, Canada.
Buensuceso A; The Mary and John Knight Translational Ovarian Cancer Research Unit, London Regional Cancer Program, London, ON, Canada.; Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Valdes YR; The Mary and John Knight Translational Ovarian Cancer Research Unit, London Regional Cancer Program, London, ON, Canada.
DiMattia GE; The Mary and John Knight Translational Ovarian Cancer Research Unit, London Regional Cancer Program, London, ON, Canada.; Department of Oncology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.; Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Shepherd TG; The Mary and John Knight Translational Ovarian Cancer Research Unit, London Regional Cancer Program, London, ON, Canada. .; Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. .; Department of Oncology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. .; Department of Obstetrics and Gynaecology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. .; London Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, ON, N6A 4L6, Canada. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Jul 14; Vol. 13 (1), pp. 11424. Date of Electronic Publication: 2023 Jul 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Ovarian Neoplasms*/pathology
Cystadenocarcinoma, Serous*/pathology
Mice ; Female ; Humans ; Animals ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism ; Gain of Function Mutation
Czasopismo naukowe
Tytuł:
Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy.
Autorzy:
Yang X; Nankai University School of Medicine, Nankai University, Tianjin, 300071, People's Republic of China.
Zheng M; Department of Pathology, Tianjin Union Medical Center, Tianjin, 300121, People's Republic of China.
Ning Y; Nankai University School of Medicine, Nankai University, Tianjin, 300071, People's Republic of China.
Sun J; Nankai University School of Medicine, Nankai University, Tianjin, 300071, People's Republic of China.
Yu Y; Nankai University School of Medicine, Nankai University, Tianjin, 300071, People's Republic of China.
Zhang S; Department of Pathology, Tianjin Union Medical Center, Tianjin, 300121, People's Republic of China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2023 Jul 11; Vol. 21 (1), pp. 456. Date of Electronic Publication: 2023 Jul 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Matrix Metalloproteinase 17*
Cystadenocarcinoma, Serous*
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/therapy
Humans ; Female ; Prognosis ; Carcinoma, Ovarian Epithelial
Czasopismo naukowe
Tytuł:
RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma.
Autorzy:
Kim K; Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.; Department of Pathology, Soonchunhyang University, Seoul, Korea.
Kim SH; Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Lee JY; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Kim YN; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Lee ST; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.
Park E; Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. .
Pokaż więcej
Źródło:
Journal of gynecologic oncology [J Gynecol Oncol] 2023 Jul; Vol. 34 (4), pp. e45. Date of Electronic Publication: 2023 Feb 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Ovarian Neoplasms*/pathology
Cystadenocarcinoma, Serous*
Female ; Humans ; Geminin ; Progression-Free Survival ; Rad51 Recombinase
Czasopismo naukowe
Tytuł:
Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Autorzy:
Bellone S; Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
McNamara B; Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
Mutlu L; Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
Demirkiran C; Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
Hartwich TMP; Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
Harold J; Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
Yang-Hartwich Y; Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
Siegel ER; Department of Biostatistics, University of Arkansas for Medical Science, Little Rock, AR 72205, USA.
Santin AD; Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 May 17; Vol. 24 (10). Date of Electronic Publication: 2023 May 17.
Typ publikacji:
Journal Article
MeSH Terms:
Circulating Tumor DNA*/genetics
Uterine Neoplasms*/diagnosis
Uterine Neoplasms*/genetics
Uterine Neoplasms*/therapy
Cystadenocarcinoma, Serous*/diagnosis
Cystadenocarcinoma, Serous*/genetics
Cystadenocarcinoma, Serous*/therapy
Carcinosarcoma*/diagnosis
Carcinosarcoma*/genetics
Carcinosarcoma*/therapy
Female ; Humans ; Neoplasm Recurrence, Local/genetics ; Biomarkers, Tumor/genetics ; Mutation
Czasopismo naukowe
Tytuł:
Effects of Follicular Fluid on Physiological Characteristics and Differentiation of Fallopian Tube Epithelial Cells Implicating for Ovarian Cancer Pathogenesis.
Autorzy:
Zhu M; Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine, South China Institute of Large Animal Models for Biomedicine, Wuyi University, Jiangmen 529000, China.
Wang N; Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine, South China Institute of Large Animal Models for Biomedicine, Wuyi University, Jiangmen 529000, China.
Wang S; Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine, South China Institute of Large Animal Models for Biomedicine, Wuyi University, Jiangmen 529000, China.
Wang Y; Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine, South China Institute of Large Animal Models for Biomedicine, Wuyi University, Jiangmen 529000, China.
Yang X; Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine, South China Institute of Large Animal Models for Biomedicine, Wuyi University, Jiangmen 529000, China.
Fan J; Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine, South China Institute of Large Animal Models for Biomedicine, Wuyi University, Jiangmen 529000, China.; Department of Molecular Pathology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi 409-3898, Japan.
Chen Y; Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine, South China Institute of Large Animal Models for Biomedicine, Wuyi University, Jiangmen 529000, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Jun 15; Vol. 24 (12). Date of Electronic Publication: 2023 Jun 15.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/pathology
Fallopian Tube Neoplasms*/pathology
Cystadenocarcinoma, Serous*/pathology
Female ; Humans ; Fallopian Tubes/pathology ; Follicular Fluid ; Epithelial Cells/pathology ; Cell Proliferation
Czasopismo naukowe
Tytuł:
SPON1 is an independent prognostic biomarker for ovarian cancer.
Autorzy:
Miyakawa R; Department of Basic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960- 1295, Japan.
Kobayashi M; Department of Basic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960- 1295, Japan. .
Sugimoto K; Department of Basic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960- 1295, Japan.
Endo Y; Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.; Department of Regional Gynecologic Oncology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Kojima M; Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.; Department of Regional Gynecologic Oncology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Kobayashi Y; Department of Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Furukawa S; Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.; Department of Regional Medical Support for Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Honda T; Department of Regional Medical Support for Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.; Department of Obstetrics and Gynecology, Iwaki City Medical Center, Iwaki, 973-8555, Japan.
Watanabe T; Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.; Department of Regional Gynecologic Oncology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Asano S; Department of Pathology, Iwaki City Medical Center, Iwaki, 973-8555, Japan.
Soeda S; Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.; Department of Regional Gynecologic Oncology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Hashimoto Y; Department of Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Fujimori K; Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.; Department of Regional Gynecologic Oncology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.; Department of Regional Medical Support for Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Chiba H; Department of Basic Pathology, Fukushima Medical University School of Medicine, Fukushima, 960- 1295, Japan. .
Pokaż więcej
Źródło:
Journal of ovarian research [J Ovarian Res] 2023 May 13; Vol. 16 (1), pp. 95. Date of Electronic Publication: 2023 May 13.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/genetics
Cystadenocarcinoma, Serous*/pathology
Fallopian Tube Neoplasms*/pathology
Adult ; Female ; Humans ; Prognosis ; Biomarkers ; Biomarkers, Tumor/metabolism
Czasopismo naukowe
Tytuł:
Endometrial Polyp in Postmenopausal Women: An Epicenter for the Development of Endometrial Serous Carcinoma.
Autorzy:
Hui P; From the Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.
Pokaż więcej
Źródło:
Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2023 Apr 01; Vol. 147 (4), pp. 413-417.
Typ publikacji:
Review; Journal Article
MeSH Terms:
Endometrial Neoplasms*/pathology
Uterine Neoplasms*/pathology
Polyps*/pathology
Carcinoma*/pathology
Cystadenocarcinoma, Serous*/pathology
Humans ; Female ; Postmenopause ; Endometrium/pathology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies